Diligence memo · auto-generated · as of July 2, 2026
Axxia Pharmaceuticals, LLC
Axxia Pharmaceuticals, LLC looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Axxia Pharmaceuticals, LLC operates in Pharmaceuticals, based in BEL AIR.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Axxia Pharmaceuticals, LLC has raised $4.2M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.0M on 2017-07-01.
Most recent recorded round closed around 2017-07-01.
Valuation (modeled)modeled
Provath models Axxia Pharmaceuticals, LLC at approximately $114M (range $2.3M–$895M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.89× the median modeled value of Seed Pharmaceuticals companies in 2016–2018 (71 peers) — value vs value, same stage and era. Issuer reports no revenue, yet is modeled well above niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 15 months.
Last raise 9.0 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 10.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 39% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 57% of those peers.
Closest niche peers: Chase Therapeutics Corp, Acura Pharmaceuticals, Inc, Paragon Biosciences Skyline Capital, LLC, Phoenix PharmaLabs Inc, Saghmos Therapeutics, Inc..
Peoplefiled
15 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.